The addition of neoadjuvant pertuzumab for the treatment of HER2+ breast cancer: a cost estimate with real-world data

The addition of neoadjuvant pertuzumab for the treatment of HER2+ breast cancer: a cost estimate with real-world data

Highlights i. The results obtained in the AC-DHP cohort, which included Pertuzumab as a NeoT, suggest better clinical outcomes compared to the AC-DH group, a confirmation based on real-world data. ii. Some patient profiles seem to be more promising concerning the overall costs for pathological compl...

Full description

Bibliographic Details
Main Authors: Andreia Borges, Filipa Pereira, Patrícia Redondo, Luís Antunes, Cláudia Vieira, Pedro Antunes, Maria José Bento, Susana Sousa, José Machado Lopes, Francisco Rocha-Gonçalves, Joaquim Abreu de Sousa, Deolinda Sousa Pereira, Marina Borges
Format: Article
Language:English
Published: BMC 2021-09-01
Series:Health Economics Review
Subjects:
Pertuzumab
Neoadjuvant treatment
HER2-positive breast cancer
Cost-effectiveness analysis
Online Access:https://doi.org/10.1186/s13561-021-00332-0

Internet

https://doi.org/10.1186/s13561-021-00332-0

Similar Items